Inflexion acquires Primed in roughly €300 million deal
Inflexion buys German medtech Primed for about €300 million, aiming to speed product development and expand Primed’s presence in hospitals across 70 countries.
Inflexion acquires Primed, a Halberstadt-based maker of single-use medical devices, in a transaction valued at roughly €300 million, according to people familiar with the matter. The purchase, by the British private equity firm, transfers ownership from Paragon Partners and signals a further wave of investment into Europe’s medical technology sector. Company spokespeople declined to comment on the terms as the deal moves toward completion.
Deal terms and valuation
Market participants estimate the transaction values Primed at approximately €300 million, although neither buyer nor seller has confirmed the figure publicly. Paragon Partners had been the owner since 2023, and the deal marks a sale of a manufacturing-focused medtech firm out of Germany’s mid-market segment. The reported price reflects demand for companies with established sterile-production capabilities and diversified clinical use cases.
Inflexion’s activity in German-speaking markets
This acquisition is the sixth transaction Inflexion has executed in the German-language region and represents the firm’s third healthcare investment there. Earlier deals in the sector included stakes in a research specialist and a veterinary clinic chain, underlining Inflexion’s recent push into health-related assets. The firm gained broader local prominence after acquiring a majority stake in a major financial portal in early 2025 in a separate multi-hundred-million-euro transaction.
Inflexion’s stated strategic approach
Inflexion has signaled a pattern of combining information and service platforms with direct commercial offerings in other sectors, and it appears to apply a similar playbook to healthcare. Executives have said in prior public statements that they pursue growth by strengthening distribution capabilities and by integrating adjacent businesses through follow-on acquisitions. For Primed, the investor has indicated an emphasis on accelerating new product development and expanding sales internationally.
Primed’s operations and market footprint
Founded in 1946 and headquartered in Halberstadt, Primed manufactures sterile, single-use medical products used across clinical settings such as radiotherapy, surgery, intensive care and nursing. The company emphasizes in-house production across multiple stages, from specialty material fabrication to final sterile packaging, a capability that supports supply reliability for hospital customers. Primed employs more than 450 people and reports that its products are used in medical facilities in more than 70 countries.
Manufacturing depth and clinical applications
Primed’s vertical integration gives it control over key quality and sterility processes, a valuable attribute in light of global demand for dependable disposable medical devices. Its product portfolio targets critical-care and procedural areas where single-use items reduce infection risk and improve workflow efficiency. That manufacturing footprint and product mix likely contributed to the buyer’s reported willingness to pay a premium relative to simpler distribution-focused peers.
Strategic rationale and growth plans
Under Inflexion ownership, Primed is expected to pursue faster development cycles for new devices while scaling sales operations overseas, both organically and via targeted acquisitions. The investor’s previous transactions suggest it will back investments in R&D and a beefed-up commercial organization to capture additional hospital contracts. Management changes and capital expenditures to increase production or broaden the product range are typical steps private equity owners have taken in similar deals.
Market reaction and sector context
Private equity activity in medtech has continued to gather momentum as buyers seek stable, margin-bearing assets with clear clinical demand and regulatory barriers to entry. Manufacturers of single-use devices have attracted interest because of recurring consumable revenues and high switching costs for hospital procurement. The deal also reflects broader consolidation trends in European healthcare manufacturing, where scale and international reach are increasingly decisive.
Parties involved in the transaction have not issued formal statements, and the timetable for regulatory approvals or closing remains unspecified. Observers will watch whether Inflexion targets further add-on acquisitions for Primed or focuses first on expanding the company’s direct sales footprint in key hospital markets.
